Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Fox

Showing results (81-90 of 127) with videos related to

Pageof 13
Sort By:
Bone Marrow Transplantation|November 13, 2021
Correction to: Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: results of a prospective observational studyJohannes Schetelig, Jennifer Hoek, Stephan Stilgenbauer, et al.
European Journal of Dermatology : EJD|May 5, 2017
A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designsMartine Bagot, Baktiar Hasan, Sean Whittaker, et al.
Bone Marrow Transplantation|August 18, 2020
Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational studyJohannes Schetelig, Jennifer Hoek, Stephan Stilgenbauer, et al.
Transplantation|October 26, 2020
Real-world Outcomes With Rituximab-based Therapy for Posttransplant Lymphoproliferative Disease Arising After Solid Organ TransplantDavid M Burns, Katherine Clesham, Yan A Hodgson, et al.
Blood Advances|August 8, 2020
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP deliveryMatthew R Wilson, Toby A Eyre, Nicolas Martinez-Calle, et al.
Bone Marrow Transplantation|November 9, 2019
Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemiaMauricette Michallet, Peter Dreger, Mohamad Sobh, et al.
Blood|April 21, 2024
Ibrutinib as part of risk-stratified treatment for posttransplant lymphoproliferative disorder: the phase 2 TIDaL trialSridhar Chaganti, Shanna Maycock, Graham McIlroy, et al.
British Journal of Haematology|July 6, 2016
NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndromeToby A Eyre, Ruth Clifford, Adrian Bloor, et al.
Blood Advances|December 1, 2023
Impact of MYC and BCL2 double expression on outcomes in primary CNS lymphoma: a UK multicenter analysisEdward Poynton, Emily Chernucha, James Day, et al.
British Journal of Haematology|February 16, 2019
Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysisToby A Eyre, Amy A Kirkwood, Sat Gohill, et al.
Pageof 13

Showing results (81-90 of 127) with videos related to

Sort By:
Pageof 13
Bone Marrow Transplantation|November 13, 2021
Correction to: Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: results of a prospective observational studyJohannes Schetelig, Jennifer Hoek, Stephan Stilgenbauer, et al.
European Journal of Dermatology : EJD|May 5, 2017
A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designsMartine Bagot, Baktiar Hasan, Sean Whittaker, et al.
Bone Marrow Transplantation|August 18, 2020
Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational studyJohannes Schetelig, Jennifer Hoek, Stephan Stilgenbauer, et al.
Transplantation|October 26, 2020
Real-world Outcomes With Rituximab-based Therapy for Posttransplant Lymphoproliferative Disease Arising After Solid Organ TransplantDavid M Burns, Katherine Clesham, Yan A Hodgson, et al.
Blood Advances|August 8, 2020
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP deliveryMatthew R Wilson, Toby A Eyre, Nicolas Martinez-Calle, et al.
Bone Marrow Transplantation|November 9, 2019
Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemiaMauricette Michallet, Peter Dreger, Mohamad Sobh, et al.
Blood|April 21, 2024
Ibrutinib as part of risk-stratified treatment for posttransplant lymphoproliferative disorder: the phase 2 TIDaL trialSridhar Chaganti, Shanna Maycock, Graham McIlroy, et al.
British Journal of Haematology|July 6, 2016
NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndromeToby A Eyre, Ruth Clifford, Adrian Bloor, et al.
Blood Advances|December 1, 2023
Impact of MYC and BCL2 double expression on outcomes in primary CNS lymphoma: a UK multicenter analysisEdward Poynton, Emily Chernucha, James Day, et al.
British Journal of Haematology|February 16, 2019
Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysisToby A Eyre, Amy A Kirkwood, Sat Gohill, et al.
Pageof 13